Neurocrine Biosciences | Los Gastos De Explotación



Operating Expenses Cambio Fecha
AbbVie USD 9.61B 6.98B 2025-03
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
ALKERMES USD 267.3M 6.09M 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amgen USD 6.78B 401M 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Cytokinetics USD 155.97M 14.7M 2024-12
Dynavax Technologies USD 73.66M 3.12M 2024-12
Exelixis USD 403.55M 82K 2025-01
Gilead Sciences USD 4.43B 687M 2025-03
Halozyme Therapeutics USD 122.51M 4.38M 2024-12
Incyte USD 847.73M 29.46M 2025-03
Ionis Pharmaceuticals USD 278M 59.4M 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Pfizer USD 10.05B 8.12B 2025-03
Prothena USD 67.02M 463K 2024-12
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Repligen USD 162.59M 41.45M 2025-03
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Teva Pharmaceutical Industries USD 3.77B 609M 2024-12
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Neurocrine Biosciences Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.